273 related articles for article (PubMed ID: 21286345)
1. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease.
Yang ZX; Shen W; Sun H
Hepatol Int; 2010 Aug; 4(4):741-8. PubMed ID: 21286345
[TBL] [Abstract][Full Text] [Related]
2. [Effects of farnesoid X receptor on lipid metabolism in L02 cells].
Hong JL; Shen W; Bai MJ
Zhonghua Gan Zang Bing Za Zhi; 2008 Dec; 16(12):935-9. PubMed ID: 19105941
[TBL] [Abstract][Full Text] [Related]
3. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease.
Higuchi N; Kato M; Shundo Y; Tajiri H; Tanaka M; Yamashita N; Kohjima M; Kotoh K; Nakamuta M; Takayanagi R; Enjoji M
Hepatol Res; 2008; 38(11):1122-9. PubMed ID: 18684130
[TBL] [Abstract][Full Text] [Related]
4. Inonotus obliquus and its bioactive compounds alleviate non-alcoholic fatty liver disease via regulating FXR/SHP/SREBP-1c axis.
Peng A; Liu S; Fang L; Zhu Z; Zhou Y; Yue S; Ma Z; Liu X; Xue S; Qiu Y; Qi R
Eur J Pharmacol; 2022 Apr; 921():174841. PubMed ID: 35278405
[TBL] [Abstract][Full Text] [Related]
5. The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator.
Shiragannavar VD; Sannappa Gowda NG; Puttahanumantharayappa LD; Karunakara SH; Bhat S; Prasad SK; Kumar DP; Santhekadur PK
Front Pharmacol; 2023; 14():1135952. PubMed ID: 36909161
[No Abstract] [Full Text] [Related]
6. Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism.
Wang S; Sheng F; Zou L; Xiao J; Li P
J Adv Res; 2021 Dec; 34():109-122. PubMed ID: 35024184
[TBL] [Abstract][Full Text] [Related]
7. The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease.
Aguilar-Olivos NE; Carrillo-Córdova D; Oria-Hernández J; Sánchez-Valle V; Ponciano-Rodríguez G; Ramírez-Jaramillo M; Chablé-Montero F; Chávez-Tapia NC; Uribe M; Méndez-Sánchez N
Ann Hepatol; 2015; 14(4):487-93. PubMed ID: 26019035
[TBL] [Abstract][Full Text] [Related]
8. Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner.
Han X; Cui ZY; Song J; Piao HQ; Lian LH; Hou LS; Wang G; Zheng S; Dong XX; Nan JX; Wu YL
Chem Biol Interact; 2019 Sep; 311():108794. PubMed ID: 31421115
[TBL] [Abstract][Full Text] [Related]
9. Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity.
Yan F; Wang Q; Lu M; Chen W; Song Y; Jing F; Guan Y; Wang L; Lin Y; Bo T; Zhang J; Wang T; Xin W; Yu C; Guan Q; Zhou X; Gao L; Xu C; Zhao J
J Hepatol; 2014 Dec; 61(6):1358-64. PubMed ID: 25016220
[TBL] [Abstract][Full Text] [Related]
10. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
[TBL] [Abstract][Full Text] [Related]
11. [Exploring effects of natural hyperoxic environment on liver lipid metabolism based on the bile acid-farnesoid X receptor pathway in sub-healthy rats].
Ouyang QY; Zhu ZX; Luo XH; Cheng ML
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):362-368. PubMed ID: 33979964
[No Abstract] [Full Text] [Related]
12. Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice.
Yan C; Zhang Y; Zhang X; Aa J; Wang G; Xie Y
Biomed Pharmacother; 2018 Sep; 105():274-281. PubMed ID: 29860219
[TBL] [Abstract][Full Text] [Related]
13. [Expression and action of hepatic sterol regulatory element-binding protein-1c in patients with nonalcoholic fatty liver disease].
Yang ZX; Sun H; Shen W
Zhonghua Gan Zang Bing Za Zhi; 2008 Nov; 16(11):823-6. PubMed ID: 19032865
[TBL] [Abstract][Full Text] [Related]
14. Population-based meta-analysis and gene-set enrichment identifies FXR/RXR pathway as common to fatty liver disease and serum lipids.
Handelman SK; Puentes YM; Kuppa A; Chen Y; Du X; Feitosa MF; Palmer ND; Speliotes EK
Hepatol Commun; 2022 Nov; 6(11):3120-3131. PubMed ID: 36098472
[TBL] [Abstract][Full Text] [Related]
15. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease.
Wu W; Zhu B; Peng X; Zhou M; Jia D; Gu J
Biochem Biophys Res Commun; 2014 Jan; 443(1):68-73. PubMed ID: 24269813
[TBL] [Abstract][Full Text] [Related]
16. Roux-en-Y Gastric Bypass Improves Metabolic Conditions in Association with Increased Serum Bile Acids Level and Hepatic Farnesoid X Receptor Expression in a T2DM Rat Model.
Yan Y; Sha Y; Huang X; Yuan W; Wu F; Hong J; Fang S; Huang B; Hu C; Wang B; Zhang X
Obes Surg; 2019 Sep; 29(9):2912-2922. PubMed ID: 31079286
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of long non-coding RNA Gm10804 suppresses disorders of hepatic glucose and lipid metabolism in diabetes with non-alcoholic fatty liver disease.
Li T; Huang X; Yue Z; Meng L; Hu Y
Cell Biochem Funct; 2020 Oct; 38(7):839-846. PubMed ID: 32212193
[TBL] [Abstract][Full Text] [Related]
18. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
19. trans-Chalcone inhibits high-fat diet-induced disturbances in FXR/SREBP-1c/FAS and FXR/Smad-3 pathways in the kidney of rats.
Alipour MR; Jeddi S; Karimi-Sales E
J Food Biochem; 2020 Nov; 44(11):e13476. PubMed ID: 32944984
[TBL] [Abstract][Full Text] [Related]
20. [Effect of Fuzi Lizhong decoction in reducing liver injury of rats with non-alcoholic fatty liver via activating AMPK and suppressing NF-κBp65 pathway].
Yang JY; Shi ZH; Ma W; Tao DQ; Liu S; Chen L; Zhou XL
Zhongguo Zhong Yao Za Zhi; 2018 Aug; 43(15):3176-3183. PubMed ID: 30200715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
